NPM1 and acute myeloid leukemia: Our recent studies highlighted an unexpected propensity of the CTD of NPMc+ to amyloid aggregation, providing cytotoxic species.[60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70] AML therapies targeting NPM1 are based on the identification of molecules capable of interfering with its functions as oligomerization, binding to other partners and localization.[71] Indeed, AML cells bearing NPM1 mutations retain a certain amount of wt protein into the nucleolus making their nucleolus more vulnerable with respect to cells expressing only wt protein.